Evaluation of Cost-Effective Therapy by Comparing Brands of the Same Formulation in Pakistan

Abstract

Abstract Views: 0

In Pakistan, where millions face the burden of healthcare costs, the choice between branded and alternative drug formulations plays a crucial role in patient outcomes. Often, branded medications are prescribed over more cost-effective options, exacerbating financial strain for patients, especially in low- and middle-income settings. The current study is crucial to address healthcare affordability, highlighting significant cost disparities between prescribed branded medications and alternatives. It critically aimed to evaluate cost-effective therapies by comparing prescribed brands with other options for cardiovascular diseases (CVDs), diabetes, neurological disorders, and paediatrics. Furthermore, the study also identified the cost-effective therapies for CVDs, diabetes, neurological disorders, and pediatric conditions between branded medications with their generic and alternative counterparts in Pakistan. This would help to achieve cost-effective therapies. Additionally, it also shed light on the hurdles faced by the regulators to impose generic prescribing across Pakistan. It may motivate healthcare providers and policymakers about the benefits of generic prescribing to provide cost-effective treatment plan which may lead towards the overall patients’ satisfaction. Data collected from various regions of Pakistan across public and private healthcare sectors revealed significant cost disparities between branded and alternative medications. The analysis conducted in the study indicated a potential cost reduction of up to 66% for CVDs, 47% for neurological disorders, and 21% and 43% for diabetes and paediatrics, respectively, by opting for alternative brands. These findings underscore the urgent need for policy reforms, promoting generic prescriptions and leveraging pharmacists' expertise to enhance affordability and accessibility in the Pakistani healthcare system.